Smart Targeting To Improve Cancer Therapeutics

References

• Urruticoechea A, Alemany R, Balart J, et al. Recent advances in cancer therapy: an overview. Curr Pharm Des. 2010;16:3–10. doi:10.2174/13816121078994184720214614
   PubMed Web of Science ®Google Scholar
• Burstein HJ, Krilov L, Aragon-Ching JP, et al. Clinical cancer advances 2017: annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol. 2017;35:1341–1367.28148207
   PubMed Web of Science ®Google Scholar
• Parkhill LA. Oral mucositis and stomatitis associated with conventional and targeted anticancer therapy. J Pharmacovigil. 2013;1:112. doi:10.4172/2329-6887.1000112
   Google Scholar
• Musha A, Shimada H, Shirai K, et al. Prediction of acute radiation mucositis using an oral mucosal dose surface model in carbon ion radiotherapy for head and neck tumors. PLoS One. 2015;10:1–10.
   Web of Science ®Google Scholar
• Cheung-Ong K, Giaever G, Nislow C. DNA-damaging agents in cancer chemotherapy: serendipity and chemical biology. Chem Biol. 2013;20:648–659.23706631
   PubMedGoogle Scholar
• Pastorelli D, Soldá C. Chemotherapy-induced nausea and vomiting (CINV): the achilles heel of oncologists. Chemother. 2015;4:154.
   Google Scholar
• Mondal J, Panigrahi AK, Khuda-Bukhsh AR. Conventional chemotherapy: problems and scope for combined therapies with certain herbal products and dietary supplements. Austin J Mol Cell Biol. 2014;1:1–10.
   Google Scholar
• Cree IA, Charlton P. Molecular chess? Hallmarks of anti-cancer drug resistance. BMC Cancer. 2017;17:10.28056859
   PubMed Web of Science ®Google Scholar
• Friberg S, Nyström AM. Nanomedicine: will it offer possibilities to overcome multiple drug resistance in cancer? J Nanobiotechnology. 2016;14:1–17.26743777
   PubMed Web of Science ®Google Scholar
• Holohan C, Van Schaeybroeck S, Longley DB, et al. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013;13:714–726. doi:10.1038/nrc359924060863
   PubMed Web of Science ®Google Scholar
• Housman G, Byler S, Heerboth S, et al. Drug resistance in cancer: an overview. Cancers. 2014;6:1769–1792. doi:10.3390/cancers603176925198391
   PubMed Web of Science ®Google Scholar
• Yuan Y, Cai T, Xia X, et al. Nanoparticle delivery of anticancer drugs overcomes multidrug resistance in breast cancer. Drug Deliv. 2016;23:3350–3357. doi:10.1080/10717544.2016.117882527098896
   PubMed Web of Science ®Google Scholar
• Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015;33:941–951. doi:10.1038/nbt.333026348965
   PubMed Web of Science ®Google Scholar
• Ravi K. Nano and microparticles as controlled drug delivery devices. J Pharm Pharm Sci. 2000;3:234–258.10994037
   PubMed Web of Science ®Google Scholar
• Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces. 2010;75:1–18.
   Google Scholar
• Guo D, Xie G, Luo J. Mechanical properties of nanoparticles: basics and applications. J Phys D Appl Phys. 2014;47:013001.
   Web of Science ®Google Scholar
• Kim KY. Nanotechnology platforms and physiological challenges for cancer therapeutics. Nanomed Nanotechnol Biol Med. 2007;3:103–110. doi:10.1016/j.nano.2006.12.002
   PubMed Web of Science ®Google Scholar
• Zhang L, Yang W, Hu C, Wang Q, Wu Y. Properties and applications of nanoparticle/microparticle conveyors with adjuvant characteristics suitable for oral vaccination. Dovepress. 2018;13:2973–2987.
   Google Scholar
• Chan JM, Valencia PM, Zhang L, et al. Polymeric nanoparticles for drug delivery. Methods Mol Biol. 2010;624:163–175.
   Google Scholar
• Arayne MS, Sultana N, Qureshi F. Nanoparticles in delivery of cardiovascular drugs. Pak J Pharm Sci. 2007;20:340–348.17604260
   PubMed Web of Science ®Google Scholar
• Ilinskaya AN, Dobrovolskaia MA. Nanoparticles and the blood coagulation system. Part II: safety concerns. Nanomedicine. 2013;8:969–981.23730696
   PubMed Web of Science ®Google Scholar
• Soo Choi H, Liu W, Misra P, et al. Renal clearance of quantum dots. Nat Biotechnol. 2007;25:1165–1170.17891134
   PubMed Web of Science ®Google Scholar
• Chen ZG. Small-molecule delivery by nanoparticles for anticancer therapy. Trends Mol Med. 2010;16:594–602.20846905
   PubMed Web of Science ®Google Scholar
• Morachis JM, Mahmoud EA, Almutairi A. Physical and chemical strategies for therapeutic delivery by using polymeric nanoparticles. Pharmacol Rev. 2012;64:505–519.22544864
   PubMed Web of Science ®Google Scholar
• Schroeder A, Heller DA, Winslow MM, et al. Treating metastatic cancer with nanotechnology. Nat Rev Cancer. 2012;12:39–50.
   Web of Science ®Google Scholar
• Muzykantov V, Muro S. Targeting delivery of drugs in the vascular system. Int J Transp Phenom. 2011;12:41–49.25328360
   PubMedGoogle Scholar
• Greish K. Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines. J Drug Target. 2007;15:457–464.17671892
   PubMed Web of Science ®Google Scholar
• Simon LC, Sabliov CM. Time analysis of poly(lactic-co-glycolic) acid nanoparticle uptake by major organs following acute intravenous and oral administration in mice and rats. Ind Biotechnol. 2013;9:19–23.
   Google Scholar
• Torchilin V. Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev. 2011;63:131–135.20304019
   PubMed Web of Science ®Google Scholar
• Upreti M, Jyoti A, Sethi P. Tumor microenvironment and nanotherapeutics. Transl Cancer Res. 2013;2:309–319.24634853
   PubMed Web of Science ®Google Scholar
• Fang J, Nakamura H, Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev. 2011;63:136–151.20441782
   PubMed Web of Science ®Google Scholar
• Maeda H, Tsukigawa K, Fang J. A retrospective 30 years after discovery of the enhanced permeability and retention effect of solid tumors: next-generation chemotherapeutics and photodynamic therapy—problems, solutions, and prospects. Microcirculation. 2016;23:173–182.26237291
   PubMed Web of Science ®Google Scholar
• Maeda H. Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity. Adv Drug Deliv Rev. 2015;91:3–6.25579058
   PubMed Web of Science ®Google Scholar
• Rajabi M, Mousa S. The role of angiogenesis in cancer treatment. Biomedicines. 2017;5(2):34.
   Google Scholar
• Islam W, Fang J, Imamura T, et al. Augmentation of the enhanced permeability and retention effect with nitric oxide-generating agents improves the therapeutic effects of nanomedicines. Mol Cancer Ther. 2018;17:2643–2653.30232144
   PubMed Web of Science ®Google Scholar
• Narang AS, Varia S. Role of tumor vascular architecture in drug delivery. Adv Drug Deliv Rev. 2011;63:640–658.21514334
   PubMed Web of Science ®Google Scholar
• Danhier F, Feron O, Préat V. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release. 2010;148:135–146.20797419
   PubMed Web of Science ®Google Scholar
• Ranganathan R, Madanmohan S, Kesavan A, et al. Nanomedicine: towards development of patient-friendly drug-delivery systems for oncological applications. Int J Nanomedicine. 2012;7:1043–1060.22403487
   PubMed Web of Science ®Google Scholar
• Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986;46:6387–6392.2946403
   PubMed Web of Science ®Google Scholar
• Cho K, Wang X, Nie S, et al. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res. 2008;14:1310–1316.18316549
   PubMed Web of Science ®Google Scholar
• Brannon-Peppas L, Blanchette JO. Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev. 2012;64:206–212.
   Web of Science ®Google Scholar
• Maeda H. Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. Bioconjug Chem. 2010;21:797–802.20397686
   PubMed Web of Science ®Google Scholar
• Haley B, Frenkel E. Nanoparticles for drug delivery in cancer treatment. Urol Oncol Semin Ori Invest. 2008;26:57–64.
   PubMed Web of Science ®Google Scholar
• Forster J, Harriss-Phillips W, Douglass M, et al. A review of the development of tumor vasculature and its effects on the tumor microenvironment. Hypoxia. 2017;5:21–32.28443291
   PubMed Web of Science ®Google Scholar
• Alexis F, Pridgen EM, Langer R, et al. Nanoparticle technologies for cancer therapy. Handb Exp Pharmacol. 2010;197:55–86.
   PubMedGoogle Scholar
• Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul. 2001;41:189–207.11384745
   PubMedGoogle Scholar
• Tang L, Yang X, Yin Q, et al. Investigating the optimal size of anticancer nanomedicine. Proc Natl Acad Sci. 2014;111:15344–15349.25316794
   PubMed Web of Science ®Google Scholar
• Biswas AK, Islam MR, Choudhury ZS, et al. Nanotechnology based approaches in cancer therapeutics. Adv Nat Sci Nanosci Nanotechnol. 2014;5:4.
   Web of Science ®Google Scholar
• Kwon IK, Lee SC, Han B, et al. Analysis on the current status of targeted drug delivery to tumors. J Control Release. 2012;164:108–114.22800574
   PubMed Web of Science ®Google Scholar
• Honary S, Zahir F. Effect of zeta potential on the properties of nano-drug delivery systems – a review (part 1). Trop J Pharm Res. 2013;12(2):255–264.
   Web of Science ®Google Scholar
• Rhame K, Dagher N. Chemistry routes for copolymer synthesis containing PEG for targeting, imaging, and drug delivery purposes. Pharmaceutics. 2019;11(7):327.
   PubMed Web of Science ®Google Scholar
• Shan NB, Vercellotti GM, White JG, et al. Blood-nanoparticle interactions and in vivo biodistribution: impact of surface PEG and ligand properties. Mol Pharm. 2012;9(8):2146–2155.22668197
   PubMed Web of Science ®Google Scholar
• Cruje C, Chithrani BD. Integration of peptides for enhanced uptake of PEGylated gold nanoparticles. J Nanosci Nanotechnol. 2015;15(3):2125–2131.26413630
   PubMed Web of Science ®Google Scholar
• Mishra P, Nayak B, Dey RK. PEGylation in anti-cancer therapy: an overview. Asian J Pharm Sci. 2016;11:337–348.
   Web of Science ®Google Scholar
• Ma SS, Ho SH, Ma SY, et al. The pharmacokinetic and pharmacodynamic properties of site-specific pegylated genetically modified recombinant human interleukin-11 in normal and thrombocytopenic monkeys. Eur J Pharm Biopharm. 2017;119:185–191.28596035
   PubMed Web of Science ®Google Scholar
• Majtan T, Bublil EM, Park I, et al. Pharmacokinetics and pharmacodynamics of PEGylated truncated human cystathionine beta-synthase for treatment of homocystinuria. Life Sci. 2018;200:15–25.29526799
   PubMed Web of Science ®Google Scholar
• Zhang F, Zhang S, Pollack SF, et al. Improving paclitaxel delivery: in vitro and in vivo characterization of PEGylated polyphosphoester-based nanocarriers. J Am Chem Soc. 2015;137:2056–2066.25629952
   PubMed Web of Science ®Google Scholar
• Jain A, Barve A, Zhao Z, et al. Targeted delivery of an siRNA/PNA hybrid nanocomplex reserves carbon tetrachloride-induced liver fibrosis. Adv Ther. 2019;2:1900046.
   Web of Science ®Google Scholar
• Zhao Z, Li Y, Shukla R, et al. Development of a biocompatible copolymer nanocomplex to deliver VEGF siRNA for triple negative breast cancer. Theranostics. 2019;9(15):4508–4524.31285776
   PubMed Web of Science ®Google Scholar
• Hatakeyama H, Akita H, Harashima H. The polyethylene glycol dilemma: advantage and disadvantage of PEGylation of liposomes for systemic genes and nucleic acids delivery to tumors. Biol Pharm Bull. 2013;36:892–899.23727912
   PubMed Web of Science ®Google Scholar
• Verhoef JJF, Anchordoquy TJ. Questioning the use of PEGylation for drug delivery. Drug Deliv Transl Res. 2013;3:499–503.24932437
   PubMed Web of Science ®Google Scholar
• Mohamed M, Abu A, Shimizu T, et al. PEGylated liposomes: immunological responses. Sci Technol Adv Mater. 2019;20(1):710–724.31275462
   PubMed Web of Science ®Google Scholar
• Shiraishi K, Yokoyama M. Toxicity and immunogenicity concerns related to PEGylated-micelle carrier systems: a review. Sci Technol Adv Mater. 2019;20(1):324–336.31068982
   PubMed Web of Science ®Google Scholar
• Fang Y, Xue J, Gao S, et al. Cleavable PEGylation: a strategy for overcoming the “PEG dilemma” in efficient drug delivery. Drug Deliv. 2017;24:22–32.29069920
   PubMed Web of Science ®Google Scholar
• Hatakeyama H, Akita H, Ito E, et al. Systemic delivery of siRNA to tumors using a lipid nanoparticle containing a tumor-specific cleavable PEG-lipid. Biomaterials. 2007;32(18):4306–4316.
   Web of Science ®Google Scholar
• Diamantis N, Banerji U. Antibody-drug conjugates - An emerging class of cancer treatment. Br J Cancer. 2016;114:362–367.26742008
   PubMed Web of Science ®Google Scholar
• Yao VJ, D’Angelo S, Butler KS, et al. Ligand-targeted theranostic nanomedicines against cancer. J Control Release. 2016;240:267–286.26772878
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–674.21376230
   PubMed Web of Science ®Google Scholar
• Jaracz S, Chen J, Kuznetsova LV, et al. Recent advances in tumor-targeting anticancer drug conjugates. Bioorg Med Chem. 2005;13:5043–5054.15955702
   PubMed Web of Science ®Google Scholar
• Steichen SD, Caldorera-Moore M, Peppas NA. A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics. Eur J Pharm Sci. 2013;48:416–427.23262059
   PubMed Web of Science ®Google Scholar
• Yang J, Yang J, Wei Y, et al. Modification of IL-24 by tumor penetrating peptide iRGD enhanced its antitumor efficacy against non-small cell lung cancer. Int Inmmunopharmacol. 2019;70:125–134.
   PubMed Web of Science ®Google Scholar
• Yu J, Sun L, Zhou J, et al. Self-assembled tumor-penetrating peptide-modified Poly(l-γ-glutamylglutamine)–paclitaxel nanoparticles based on hydrophobic interaction for the treatment of glioblastoma. Bioconjug Chem. 2017;28:2823–2831.28968068
   PubMed Web of Science ®Google Scholar
• Rosenblum D, Joshi D, Tao W, et al. Progress and challenges towards targeted delivery of cancer therapeutics. Nat Commun. 2018;9:1410.29650952
   PubMed Web of Science ®Google Scholar
• Siwak DR, Carey M, Hennessy BT, et al. Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges. J Oncol. 2010;2010:1–20.
   Google Scholar
• Maeda H, Bharate GY, Daruwalla J. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur J Pharm Biopharm. 2009;71:409–419.19070661
   PubMed Web of Science ®Google Scholar
• Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer. 2012;12:278–287.22437872
   PubMed Web of Science ®Google Scholar
• Solomon M, Liu Y, Berezin MY, et al. Optical imaging in cancer research: basic principles, tumor detection, and therapeutic monitoring. Med Princ Pract. 2011;20:397–415.21757928
   PubMed Web of Science ®Google Scholar
• Li HJ, Du JZ, Du XJ, et al. Stimuli-responsive clustered nanoparticles for improved tumor penetration and therapeutic efficacy. PNAS. 2016;113:4164–4169.27035960
   PubMed Web of Science ®Google Scholar
• Ruoslahti E, Bhatia SN, Sailor MJ. Targeting of drugs and nanoparticles to tumors. J Cell Biol. 2010;188:759–768.20231381
   PubMed Web of Science ®Google Scholar
• Kolate A, Baradia D, Patil S, et al. PEG — A versatile conjugating ligand for drugs and drug delivery systems. J Control Release. 2014;192:67–81.24997275
   PubMed Web of Science ®Google Scholar
• Bao W, Liu R, Wang Y, et al. PLGA-PLL-PEG-Tf-based targeted nanoparticles drug delivery system enhance antitumor efficacy via intrinsic apoptosis pathway. Int J Nanomedicine. 2015;10:557–566.25609961
   PubMed Web of Science ®Google Scholar
• Cruz LJ, Tacken PJ, Fokkink R, et al. The influence of PEG chain length and targeting moiety on antibody-mediated delivery of nanoparticle vaccines to human dendritic cells. Biomaterials. 2011;32:6791–6803.21724247
   PubMed Web of Science ®Google Scholar
• Su YC, Burnouf PA, Chuang KH, et al. Conditional internalization of PEGylated nanomedicines by PEG engagers for triple negative breast cancer therapy. Nat Commun. 2017;8:15507.28593948
   PubMed Web of Science ®Google Scholar
• Sun H, Zu Y. Aptamers and their applications in nanomedicine. Small. 2015;11:2352–2364.25677591
   PubMed Web of Science ®Google Scholar
• Pérez-Herrero E, Fernández-Medarde A. Advanced targeted therapies in cancer: drug nanocarriers, the future of chemotherapy. Eur J Pharm Biopharm. 2015;93:52–79.25813885
   PubMed Web of Science ®Google Scholar
• Yoo J, Park C, Yi G, Lee D, Koo H. Active targeting strategies using biological ligands for nanoparticle drug delivery systems. Cancers. 2019;11(5):640.
   PubMed Web of Science ®Google Scholar
• Fernández M, Javaid F, Chudasama V. Advances in targeting the folate receptor in the treatment/imaging of cancers. Chem Sci. 2017;9:790–810.29675145
   PubMed Web of Science ®Google Scholar
• Srinivasarao M, Galliford CV, Low PS. Principles in the design of ligand-targeted cancer therapeutics and imaging agents. Nat Rev Drug Discov. 2015;14:203–219.25698644
   PubMed Web of Science ®Google Scholar
• Yang Y, Li N, Nie Y, et al. Folate-modified poly(malic acid) graft polymeric nanoparticles for targeted delivery of doxorubicin: synthesis, characterization and folate receptor expressed cell specificity. J Biomed Nanotechnol. 2015;11:1628–1639.26485931
   PubMed Web of Science ®Google Scholar
• Xing L, Xu Y, Sun K, et al. Identification of a peptide for folate receptor alpha by phage display and its tumor targeting activity in ovary cancer xenograft. Sci Rep. 2018;8:8426.29849110
   PubMed Web of Science ®Google Scholar
• Cal P, Frade R, Chudasama V, et al. Targeting cancer cells with folic acid-iminoboronate fluorescent conjugates. Chem Commun. 2014;50:5261–5263.
   PubMed Web of Science ®Google Scholar
• Assaraf Y, Leamon C, Reddy J. The folate receptor as a rational therapeutic target for personalized cancer treatment. Drug Resist Updat. 2014;17:89–95.25457975
   PubMed Web of Science ®Google Scholar
• Fernández M, Javaid F, Chudasama V. Advances in targeting the folate receptor in the treatment/imaging of cancers. Chem Sci. 2018;4:790–810.
   Web of Science ®Google Scholar
• Zwicke GL, Ali Mansoori GA, Jeffery CJ. Utilizing the folate receptor for active targeting of cancer nanotherapeutics. Nano Rev. 2012;3:18496.
   PubMedGoogle Scholar
• Shi H, Guo J, Li C, et al. A current review of folate receptor alpha as a potential tumor target in non-small-cell lung cancer. Drug Des Devel Ther. 2015;9:4989–4996.
   PubMed Web of Science ®Google Scholar
• Shen J, Hu Y, Putt KS, et al. Assessment of folate receptor alpha and beta expression in selection of lung and pancreatic cancer patients for receptor targeted therapies. Oncotarget. 2018;9:4485–4495.29435118
   PubMedGoogle Scholar
• Shen J, Putt KS, Visscher DW, et al. Assessment of folate receptor-beta expression in human neoplastic tissues. Oncotarget. 2015;6:14700–14709.25909292
   PubMedGoogle Scholar
• Morales-Cruz M, Cruz-Montañez A, Figueroa CM, et al. Combining stimulus-triggered release and active targeting strategies improves cytotoxicity of cytochrome c nanoparticles in tumor cells. Mol Pharm. 2016;13:2844–2854.27283751
   PubMed Web of Science ®Google Scholar
• Kawamoto M, Horibe T, Kohno M, et al. A novel transferrin receptor-targeted hybrid peptide disintegrates cancer cell membrane to induce rapid killing of cancer cells. BMC Cancer. 2011;11:359.21849092
   PubMed Web of Science ®Google Scholar
• Daniels TR, Bernabeu E, Rodríguez JA, et al. The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochim Biophys Acta Gen Subj. 2012;1820(3):291–317. doi:10.1016/j.bbagen.2011.07.016
   PubMed Web of Science ®Google Scholar
• Shen Y, Li X, Dong D, et al. Transferrin receptor 1 in cancer: a new sight for cancer therapy. Am J Cancer Res. 2018;8:916–931.30034931
   PubMed Web of Science ®Google Scholar
• Shimosaki S, Nakahata S, Ichikawa T, et al. Development of a complete human IgG monoclonal antibody to transferrin receptor 1 targeted for adult T-cell leukemia/lymphoma. Biochem Biophys Res Commun. 2017;485:144–151. doi:10.1016/j.bbrc.2017.02.03928189691
   PubMed Web of Science ®Google Scholar
• Daniels-Wells T, Widney D, Leoh L, et al. Efficacy of an anti-transferrin receptor 1 antibody against AIDS-related non-hodgkin lymphoma: a brief communication. J Immunother. 2015;38:307–310. doi:10.1097/CJI.000000000000009226325374
   PubMed Web of Science ®Google Scholar
• Leoh L, Kim YK, Candelaria P, et al. Efficacy and mechanism of antitumor activity of an antibody targeting transferrin receptor 1 in mouse models of human multiple myeloma. J Immunol. 2018;200:3485–3494. doi:10.4049/jimmunol.170078729654211
   PubMed Web of Science ®Google Scholar
• Saxena M, Delgado Y, Sharma RK, et al. Inducing cell death in vitro in cancer cells by targeted delivery of cytochrome c via a transferrin conjugate. PLoS One. 2018;13:e0195542. doi:10.1371/journal.pone.019554229649293
   PubMed Web of Science ®Google Scholar
• Heinemann V, Stintzing S, Kirchner T, et al. Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR. Cancer Treat Rev. 2009;35:262–271. doi:10.1016/j.ctrv.2008.11.00519117687
   PubMed Web of Science ®Google Scholar
• Creixell M, Bohórquez A, Torres-Lugo M, et al. EGFR-targeted magnetic nanoparticle heaters kill cancer cells without a perceptible temperature rise. ACS Nano. 2011;5:7124–7129. doi:10.1021/nn202666w21838221
   PubMed Web of Science ®Google Scholar
• Thorne AH, Zanca C, Furnari F. Epidermal growth factor receptor targeting and challenges in glioblastoma. Neuro Oncol. 2016;18:914–918. doi:10.1093/neuonc/nov31926755074
   PubMed Web of Science ®Google Scholar
• Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol. 2006;33:369–385. doi:10.1053/j.seminoncol.2006.04.00316890793
   PubMed Web of Science ®Google Scholar
• Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immuno therapy. Nat Rev Immunol. 2010;10:317–327. doi:10.1038/nri2744.20414205
   PubMed Web of Science ®Google Scholar
• Hartimath SV, Alizadeh E, Solomon VR, et al. Preclinical evaluation of 111 in-labeled PEGylated maytansine nimotuzumab drug conjugates in EGFR-positive cancer models. J Nucl Med. 2019;17:118.
   Google Scholar
• Poiroux G, Barre A, Van Damme EJM, et al. Plant lectins targeting O-glycans at the cell surface as tools for cancer diagnosis, prognosis and therapy. Int J Mol Sci. 2017;18:1232. doi:10.3390/ijms18061232
   PubMed Web of Science ®Google Scholar
• Binkhathlan Z, Lavasanifar A. P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: current status and future perspectives. Curr Cancer Drug Targets. 2013;13:326–346. doi:10.2174/1568009611313999007623369096
   PubMed Web of Science ®Google Scholar
• Nobili S, Landini I, Mazzei T, et al. Overcoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expression. Med Res Rev. 2012;32:1220–1262. doi:10.1002/med.2023921374643
   PubMed Web of Science ®Google Scholar
• Shimomura O, Oda T, Tateno H, et al. A novel therapeutic strategy for pancreatic cancer: targeting cell surface glycan using rBC2LC-N lectin-drug conjugate (LDC). Mol Cancer Ther. 2018;17:183–195. doi:10.1158/1535-7163.MCT-17-023228939555
   PubMed Web of Science ®Google Scholar
• Sherman L, Sleeman J, Herrlich P, et al. Hyaluronate receptors: key players in growth, differentiation, migration and tumor progression. Curr Opin Cell Biol. 1994;6:726–733. doi:10.1016/0955-0674(94)90100-77530464
   PubMed Web of Science ®Google Scholar
• Misra S, Hascall VC, Markwald RR, Ghatak S. Interactions between hyaluronan and its receptors (CD44, RHAMM) regulate the activities of inflammation and cancer. Front Immunol. 2015;6:201.25999946
   PubMed Web of Science ®Google Scholar
• De la Motte CA, Drazba JA. Viewing hyaluronan: imaging contributes to imagining new roles for this amazing matrix polymer. J Histochem Cytochem. 2011;59(3):252–257. doi:10.1369/002215541141381721378279
   PubMed Web of Science ®Google Scholar
• Shigeishi H, Higashikawa K, Takechi M. Role of receptor for hyaluronan-mediated motility (RHAMM) in human head and neck cancers. J Cancer Res Clin Oncol. 2014;140:1629–1640. doi:10.1007/s00432-014-1653-z24676428
   PubMed Web of Science ®Google Scholar
• Chen C, Zhao S, Karnad A, Freeman JW. The biology and role of CD44 in cancer progression: therapeutic implications. J Hematol Oncol. 2018;11(1):64. doi:10.1186/s13045-018-0605-529747682
   PubMed Web of Science ®Google Scholar
• Yin T, Wang G, He S, et al. Human cancer cells with stem cell-like phenotype exhibit enhanced sensitivity to the cytotoxicity of IL-2 and IL-15 activated natural killer cells. Cell Immunol. 2016;300:41–45. doi:10.1016/j.cellimm.2015.11.00926677760
   PubMed Web of Science ®Google Scholar
• Cadete A, Alonso MJ. Targeting cancer with hyaluronic acid-based nanocarriers: recent advances and translational perspectives. Nanomedicine. 2016;11:2341–2357. doi:10.2217/nnm-2016-023327526874
   PubMed Web of Science ®Google Scholar
• Edelman R, Assaraf YG, Levitzky I, et al. Hyaluronic acid-serum albumin conjugate-based nanoparticles for targeted cancer therapy. Oncotarget. 2017;8:24337–24353. doi:10.18632/oncotarget.1536328212584
   PubMed Web of Science ®Google Scholar
• Figueroa CM, Morales-Cruz M, Surarez BN, et al. Induction of cancer cell death by hyaluronic acid-mediated uptake of cytochrome c. J Nanomed Nanotechnol. 2015;6:316.27182458
   PubMedGoogle Scholar
• Montagner IM, Merlo A, Carpanese D, et al. Drug conjugation to hyaluronan widens therapeutic indications for ovarian cancer. Oncoscience. 2015;2:373–381. doi:10.18632/oncoscience.15026097871
   PubMedGoogle Scholar
• Raucher D, Ryu JS. Cell-penetrating peptides: strategies for anticancer treatment. Trends Mol Med. 2015;21:560–570. doi:10.1016/j.molmed.2015.06.00526186888
   PubMed Web of Science ®Google Scholar
• Feni L, Neundorf I. The current role of cell-penetrating peptides in cancer therapy. Adv Exp Med Biol. 2017;1030:279–295.29081059
   PubMed Web of Science ®Google Scholar
• Taha A, Selma MH, Jawad A, et al. Improvement of cancer therapy by TAT peptide conjugated gold nanoparticles. J Clust Sci. 2019;30(2):403–414. doi:10.1007/s10876-019-01497-9
   Web of Science ®Google Scholar
• Gronewold A, Horn M, Neundorf I. Design and biological characterization of novel cell-penetrating peptides preferentially targeting cell nuclei and subnuclear regions. Beilstein J Org Chem. 2018;14:1378–1388. doi:10.3762/bjoc.14.11629977402
   PubMed Web of Science ®Google Scholar
• Hsieh TH, Hsu CY, Tsai CF, et al. A novel cell-penetrating peptide suppresses breast tumorigenesis by inhibiting β-catenin/LEF-1 signaling. Sci Rep. 2016;6:19156. doi:10.1038/srep1915626750754
   PubMed Web of Science ®Google Scholar
• El-Sayed NS, Shizari AN, Sajid MI, et al. Synthesis and antiproliferative activities of conjugates of paclitaxel and camptothecin with a cyclic cell-penetrating peptide. Molecules. 2019;24(7):E1427. doi:10.3390/molecules2407142730978971
   PubMed Web of Science ®Google Scholar
• Li W, Jia H, Wang J, et al. A CD44-specific peptide, RP-1, exhibits capacities of assisting diagnosis and predicting prognosis of gastric cancer. Oncotarget. 2017;8:30063–30076.28415792
   PubMedGoogle Scholar
• Zhang D, Jia H, Wang Y, et al. A CD44 specific peptide developed by phage display for targeting gastric cancer. Biotechnol Lett. 2015;37(11):2311–2320. doi:10.1007/s10529-015-1896-z26140900
   PubMed Web of Science ®Google Scholar
• Finlayson M. Modulation of CD44 activity by A6-peptide. Front Immunol. 2015;6:135. doi:10.3389/fimmu.2015.0013525870596
   PubMed Web of Science ®Google Scholar
• Nitta SK, Numata K. Biopolymer-based nanoparticles for drug/gene delivery and tissue engineering. Int J Mol Sci. 2013;14:1629–1654. doi:10.3390/ijms1401162923344060
   PubMed Web of Science ®Google Scholar
• Fosgerau K, Hoffmann T. Peptide therapeutics: current status and future directions. Drug Discov Today. 2015;20(1):122–128. doi:10.1016/j.drudis.2014.10.00325450771
   PubMed Web of Science ®Google Scholar
• Usmani SS, Bedi G, Samuel JS, et al. THPdb: database of FDA-approved peptide and protein therapeutics. PLoS One. 2017;12:e0181748. doi:10.1371/journal.pone.018174828759605
   PubMed Web of Science ®Google Scholar
• Tao C, Chuah YJ, Xu C, et al. Albumin conjugates and assemblies as versatile bio-functional additives and carriers for biomedical applications. J Mater Chem B. 2019;7:357–367. doi:10.1039/c9tb00665f
   PubMed Web of Science ®Google Scholar
• Gradishar WJ, Krasnojon D, Cheporov S, et al. Albumin-bound paclitaxel (ab-pac) versus docetaxel for first-line treatment of metastatic breast cancer (MBC): final overall survival (OS) analysis of a randomized phase II trial. J Clin Oncol. 2017;29(27):275. doi:10.1200/jco.2011.29.27_suppl.275
   Web of Science ®Google Scholar
• ClinicalTrials.gov. Trial of FOLF(HA)Iri versus FOLFIRI in mCRC (FOLF(HA)iri). Available from: http://clinicaltrials.gov/show/NCT01290783 Accessed June 30, 2019.
   Google Scholar
• Gibbs P, Clingan PR, Ganju V, et al. Hyaluronan-irinotecan improves progression-free survival in 5-fluorouracil refractory patients with metastatic colorectal cancer: a randomized phase II trial. Cancer Chemother Pharmacol. 2011;67:153–163. doi:10.1007/s00280-010-1303-320333384
   PubMed Web of Science ®Google Scholar
• Gordon E, Hall F. Rexin-G, a targeted genetic medicine for cancer. Expert Opin Biol Ther. 2010;10:819–832. doi:10.1517/14712598.2010.48166620384524
   PubMed Web of Science ®Google Scholar
• Waite CL, Roth CM. Nanoscale drug delivery systems for enhanced drug penetration into solid tumors: current progress and opportunities. Crit Rev Biomed Eng. 2012;40:21–41. doi:10.1615/CritRevBiomedEng.v40.i122428797
   PubMedGoogle Scholar
• Burger AM, Hartung G, Stehle G, et al. Pre-clinical evaluation of a methotrexate-albumin conjugate (MTX-HSA) in human tumor xenografts in vivo. Int J Cancer. 2001;92:718–724. doi:10.1002/1097-0215(20010601)92:5<718::aid-ijc1257>3.0.co;2-d11340578
   PubMed Web of Science ®Google Scholar
• Kaur K, Singh I, Kaur P, et al. Food and drug administration (FDA) approved peptide drugs. Asian J Res Biol Pharm Sci. 2015;3:75–88.
   Google Scholar
• Ma L, Wang C, He Z, et al. Peptide-drug conjugate: a novel drug design approach. Curr Med Chem. 2017;25:3373–3396.
   Google Scholar
• Lau JL, Dunn MK. Therapeutic peptides: historical perspectives, current development trends, and future directions. Bioorg Med Chem. 2018;26:2700–2707. doi:10.1016/j.bmc.2017.06.05228720325
   PubMed Web of Science ®Google Scholar
• Kurzrock R, Gabrail N, Chandhasin C, et al. Safety, pharmacokinetics, and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors. Mol Cancer Ther. 2012;11:308–316. doi:10.1158/1535-7163.MCT-11-0824-T22203732
   PubMed Web of Science ®Google Scholar
• Sun L-C, Mackey LV, Luo J, et al. Targeted chemotherapy using a cytotoxic somatostatin conjugate to inhibit tumor growth and metastasis in nude mice. Clin Med Oncol. 2008;2:491–499.21892324
   PubMedGoogle Scholar
• Moody T, Mantey S, Pradhan T, et al. Development of high affinity camptothecin-bombesin conjugates that have targeted cytotoxicity for bombesin receptor-containing tumor. J Biol Chem. 2004;279(22):23580−23589. doi:10.1074/jbc.M40193820015016826
   PubMed Web of Science ®Google Scholar
• Moody T, Sun L, Mantey S, et al. In vitro and in vivo antitumor effects of cytotoxic camptothecin-bombesin conjugates are mediated by specific interaction with cellular bombesin. J Pharmacol Exp Ther. 2006;318(3):1265−1272. doi:10.1124/jpet.106.10414116766720
   PubMed Web of Science ®Google Scholar
• Guan H, McGuire MJ, Li S, et al. Peptide-targeted polyglutamic acid doxorubicin conjugates for the treatment of αvβ6-positive cancers. Bioconjug Chem. 2008;19:1813–1821. doi:10.1021/bc800154f18710273
   PubMed Web of Science ®Google Scholar
• Chen X, Plasencia C, Hou Y, Neamati N. Synthesis and biological evaluation of dimeric RGD peptide-paclitaxel conjugate as a model for integrin-targeted drug delivery. J Med Chem. 2005;48:1098–1106. doi:10.1021/jm049494r15715477
   PubMed Web of Science ®Google Scholar
• Kim JW, Lee HS. Tumor targeting by doxorubicin-RGD-4C peptide conjugate in an orthotopic mouse hepatoma model. Int J Mol Med. 2004;14:529–535.15375578
   PubMed Web of Science ®Google Scholar
• Burkhart DJ, Kalet BT, Coleman MP, Post GC, Koch TH. Doxorubicin-formaldehyde conjugates targeting alphavbeta3 integrin. Mol Cancer Ther. 2004;3(12):1593–1604.15634653
   PubMed Web of Science ®Google Scholar
• Kim H, Lee Y, Kang S, et al. Self-assembled nanoparticles comprising aptide-SN38 conjugates for use in targeted cancer therapy. Nanotechnology. 2016;27(48). doi:10.1088/0957-4484/27/36/365202.
   Web of Science ®Google Scholar
• Kim H, Lee Y, Lee IH, et al. Synthesis and therapeutic evaluation of an aptide-docetaxel conjugate targeting tumor-associated fibronectin. J Control Release. 2014;178:118−124. doi:10.1016/j.jconrel.2014.01.01524462899
   PubMed Web of Science ®Google Scholar
• Tai W, Shukla RS, Qin B, et al. Development of a peptide-drug conjugate for prostate cancer therapy. Mol Pharm. 2011;8:901–912. doi:10.1021/mp200125j21510670
   PubMed Web of Science ®Google Scholar
• Hamley IW. PEG-peptide conjugates. Biomacromolecules. 2014;15(5):1543–1559. doi:10.1021/bm500246w24720400
   PubMed Web of Science ®Google Scholar
• Kim H, Hwang D, Choi M, et al. Antibody-assisted delivery of a peptide-drug conjugate for targeted cancer therapy. Mol Pharm. 2019;16(1):165–172. doi:10.1021/acs.molpharmaceut.9b0042230521347
   PubMed Web of Science ®Google Scholar
• Raza A, Rasheed T, Nabeel F, Hayat U, Bilal M, Iqbal H. Endogenous and exogenous stimuli-responsive drug delivery systems for programmed site-specific release. Molecules. 2019;24(6):1117. doi:10.3390/molecules24061117
   PubMed Web of Science ®Google Scholar
• Justus CR, Dong L, Yang LV. Acidic tumor microenvironment and pH-sensing G protein-coupled receptors. Front Physiol. 2013;4:354. doi:10.3389/fphys.2013.0035424367336
   PubMed Web of Science ®Google Scholar
• Barar J, Omidi Y. Dysregulated pH in tumor microenvironment checkmates cancer therapy. Bioimpacts. 2013;3(4):149–162. doi:10.5681/bi.2013.03624455478
   PubMedGoogle Scholar
• Kato Y, Ozawa S, Miyamoto C, et al. Acidic extracellular microenvironment and cancer. Cancer Cell Int. 2013;13:89. doi:10.1186/1475-2867-13-8924004445
   PubMed Web of Science ®Google Scholar
• Dalela M, Shrivastav TG, Kharbanda S, Singh H. pH-sensitive biocompatible nanoparticles of paclitaxel-conjugated poly(styrene-co-maleic acid) for anticancer drug delivery in solid tumors of syngeneic mice. ACS Appl Mater Interfaces. 2015;7:26530–26548. doi:10.1021/acsami.5b0776426528585
   PubMed Web of Science ®Google Scholar
• Ding HM, Ma YQ. Controlling cellular uptake of nanoparticles with pH-sensitive polymers. Sci Rep. 2013;3:2804. doi:10.1038/srep0280424076598
   PubMed Web of Science ®Google Scholar
• Kim D, Lee ES, Park K, et al. Doxorubicin loaded pH-sensitive micelle: antitumoral efficacy against ovarian A2780/DOXR tumor. Pharm Res. 2008;25:2074–2082. doi:10.1007/s11095-007-9382-518449626
   PubMed Web of Science ®Google Scholar
• Chuang CH, Wu PC, Tsai TH, et al. Development of pH-sensitive cationic PEGylated solid lipid nanoparticles for selective cancer-targeted therapy. J Biomed Nanotechnol. 2017;13(2):192–203. doi:10.1166/jbn.2017.233829377649
   PubMed Web of Science ®Google Scholar
• Zhao G, Long L, Zhang L, et al. Smart pH-sensitive nanoassemblies with cleavable PEGylation for tumor targeted drug delivery. Sci Rep. 2017;7:3383. doi:10.1038/s41598-017-03111-228611459
   PubMed Web of Science ®Google Scholar
• Liu Y, Wang W, Yang J, et al. Sun J. pH-sensitive polymeric micelles triggered drug release for extracellular and intracellular drug targeting delivery. Asian J Pharm Sci. 2013;8:159–167. doi:10.1016/j.ajps.2013.07.021
   Google Scholar
• Zhou L, Cheng R, Tao H, et al. Endosomal pH-activatable poly(ethylene oxide)-graft-doxorubicin prodrugs: synthesis, drug release, and biodistribution in tumor-bearing mice. Biomacromolecules. 2011;15(5):1460–1467. doi:10.1021/bm101340u
   Web of Science ®Google Scholar
• Lushchak VI. Glutathione homeostasis and functions: potential targets for medical interventions. J Amino Acids. 2012;2012:1–26. doi:10.1155/2012/736837
   Google Scholar
• Mortera R, Vivero-Escoto J, Slowing II, et al. Cell-induced intracellular controlled release of membrane impermeable cysteine from a mesoporous silica nanoparticle-based drug delivery system. Chem Commun. 2009;22:3219–3221. doi:10.1039/b900559e
   PubMed Web of Science ®Google Scholar
• Hong R, Han G, Fernández JM, et al. Glutathione-mediated delivery and release using monolayer protected nanoparticle carriers. J Am Chem Soc. 2006;128:1078–1079. doi:10.1021/ja056726i16433515
   PubMed Web of Science ®Google Scholar
• Méndez J, Monteagudo A, Griebenow K. Stimulus-responsive controlled release system by covalent immobilization of an enzyme into mesoporous silica nanoparticles. Bioconjug Chem. 2012;23:698–704. doi:10.1021/bc200301a22375899
   PubMed Web of Science ®Google Scholar
• Zhao M, Biswas A, Hu B, et al. Redox-responsive nanocapsules for intracellular protein delivery. Biomaterials. 2011;32:5223–5230. doi:10.1016/j.biomaterials.2011.03.06021514660
   PubMed Web of Science ®Google Scholar
• Morales-Cruz M, Figueroa CM, González-Robles T, et al. Activation of caspase-dependent apoptosis by intracellular delivery of cytochrome c-based nanoparticles. J Nanobiotechnol. 2014;12:33. doi:10.1186/s12951-014-0033-9
   PubMed Web of Science ®Google Scholar
• Figueroa CM, Suárez BN, Molina AM, et al. Smart release nano-formulation of cytochrome C and hyaluronic acid induces apoptosis in cancer cells. J Nanomed Nanotechnol. 2017;8:427.28706754
   PubMedGoogle Scholar
• Choi KY, Swierczewska M, Lee S, et al. Protease-activated drug development. Theranostics. 2012;2:156–179. doi:10.7150/thno.406822400063
   PubMed Web of Science ®Google Scholar
• Graeser R, Chung D, Esser N, et al. Synthesis and biological evaluation of an albumin-binding prodrug of doxorubicin that is cleaved by prostate-specific antigen (PSA) in a PSA-positive orthotopic prostate carcinoma model (LNCaP). Int J Cancer. 2008;122:1145–1154.17973264
   PubMed Web of Science ®Google Scholar
• Chipman S, Oldham F, Pezzoni G, et al. Biological and clinical characterization of paclitaxel poliglumex (PPX, CT-2103), a macromolecular polymer-drug conjugate. Int J Nanomedicine. 2006;1:375–383.17722272
   PubMed Web of Science ®Google Scholar
• Pillai G. Nanomedicines for cancer therapy: an update of FDA approved and those under various stages of development. SOJ Pharm Pharm Sci. 2014;1:1–13.
   Google Scholar
• Kwiatkowski S, Knap B, Przystupski D, et al. Photodynamic therapy - mechanisms, photosensitizers and combinations. Biomed Pharmacother. 2018;106:1098–1107.30119176
   PubMed Web of Science ®Google Scholar
• Gray MD, Lyon PC, Mannaris C, et al. Focused ultrasound hyperthermia for targeted drug release from thermosensitive liposomes: results from a phase I trial. Radiology. 2019;291:232–238.30644817
   PubMed Web of Science ®Google Scholar
• Agostinis P, Berg K, Cengel KA, et al. Photodynamic therapy of cancer: an update. CA Cancer J Clin. 2011;61:250–281.21617154
   PubMed Web of Science ®Google Scholar
• Dos Santos AF, Queiroz de Almeida DR, Terra LF, et al. Photodynamic therapy in cancer treatment - an update review. J Cancer Metastasis Treat. 2019;5:25.
   Google Scholar
• Van Straten D, Mashayekhi V, De Bruijn HS, et al. Oncologic photodynamic therapy: basic principles, current clinical status and future directions. Cancers. 2017;9(2):19.
   PubMed Web of Science ®Google Scholar
• Hong EJ, Choi DG, Shim MS. Targeted and effective photodynamic therapy for cancer using functionalized nanomaterials. Acta Pharm Sin B. 2016;6:297–307.27471670
   PubMed Web of Science ®Google Scholar
• Liang P, Huang K, Tung C, et al. A novel photodynamic therapy-based drug delivery system layered on a stent for treating cholangiocarcinoma. Biomed Microdevices. 2018;20:3.
   Web of Science ®Google Scholar
• Alves L, Ferreira L, Pacheco P, et al. Pore forming channels as a drug delivery system for photodynamic therapy in cancer associated with nanoscintillators. Oncotarget. 2018;9:25342–25354.29861876
   PubMedGoogle Scholar
• Calixto G, Bernegossi J, De Freitas L, et al. Nanotechnology-based drug delivery systems for photodynamic therapy of cancer: A review. Molecules. 2016;21:342.26978341
   PubMed Web of Science ®Google Scholar
• Molina AM, Morales-Cruz M, Cindy M, et al. Function as delivery system for photodynamic cancer therapy. J Nanomed Naotechnol. 2016;6:1–20.
   Google Scholar
• Tu J, Wang T, Shi W, et al. Multifunctional ZnPc-loaded mesoporous silica nanoparticles for enhancement of photodynamic therapy efficacy by endolysosomal escape. Biomaterials. 2012;33:7903–7914.22840227
   PubMed Web of Science ®Google Scholar
• Molina AM, Morales-Cruz M, Benítez M, et al. Redox-sensitive cross-linking enhances albumin nanoparticle function as delivery system for photodynamic cancer therapy. J Nanomed Nanotechnol. 2016;3.
   Google Scholar
• Veiseh O, Sun C, Fang C, et al. Specific targeting of brain tumors with an optical/magnetic resonance imaging nanoprobe across the blood-brain barrier. Cancer Res. 2009;69:6200–6207.19638572
   PubMed Web of Science ®Google Scholar
• Dong X. Current strategies for brain drug delivery. Theranostics. 2018;8:1481–1493.29556336
   PubMed Web of Science ®Google Scholar
• Longmire M, Choyke PL, Kobayashi H. Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats. Nanomedicine. 2008;3:703–717.18817471
   PubMed Web of Science ®Google Scholar
• Azarmi S, Roa WH, Löbenberg R. Targeted delivery of nanoparticles for the treatment of lung diseases. Adv Drug Deliv Rev. 2008;60:863–875.18308418
   PubMed Web of Science ®Google Scholar
• Rijt SH, Bein T, Meiners S. Medical nanoparticles for next generation drug delivery to the lungs. Eur Resp J. 2014;44:765–774.
   PubMed Web of Science ®Google Scholar
• Perry JL, Reuter KG, Luft JC, et al. Mediating passive tumor accumulation through particle size, tumor type, and location. Nano Lett. 2017;17:2879–2886.28287740
   PubMed Web of Science ®Google Scholar
• Yoshida M, Takimoto R, Murase K, et al. Targeting anticancer drug delivery to pancreatic cancer cells using a fucose-bound nanoparticle approach. PLoS One. 2012;7:e39545.22808043
   PubMed Web of Science ®Google Scholar
• Guarneri V, Frassoldati A, Bottini A, et al. Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study. J Clin Oncol. 2012;30:1989–1995.22493419
   PubMed Web of Science ®Google Scholar
• Stish BJ, Chen H, Shu Y, et al. A bispecific recombinant cytotoxin (DTEGF13) targeting human interleukin-13 and epidermal growth factor receptors in a mouse xenograft model of prostate cancer. Clin Cancer Res. 2007;13:6486–6493.17975161
   PubMed Web of Science ®Google Scholar
• Goldstein R, Hanley C, Morris J, et al. Clinical investigation of the role of interleukin-4 and interleukin-13 in the evolution of prostate cancer. Cancers (Basel). 2011;3(4):4281–4293.24213139
   PubMedGoogle Scholar
• Yau T, Dan X, Ng CC, et al. Lectins with potential for anti-cancer therapy. Molecules. 2015;20:3791–3810.25730388
   PubMed Web of Science ®Google Scholar
• Luria-Pérez R, Helguera G, Rodríguez JA. Antibody-mediated targeting of the transferrin receptor in cancer cells. Bol Med Hosp Infant Mex. 2016;73:372–379.29421281
   PubMed Web of Science ®Google Scholar
• Bazak R, Houri M, El Achy S, et al. Cancer active targeting by nanoparticles: a comprehensive review of literature. J Cancer Res Clin Oncol. 2015;141:769–784.25005786
   PubMed Web of Science ®Google Scholar
• Padró T, Bieker R, Ruiz S, et al. Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia. Leukemia. 2002;16:1302–1310.12094254
   PubMed Web of Science ®Google Scholar